Neurocrine Biosciences is reportedly in advanced discussions to acquire Soleno Therapeutics for a valuation exceeding $2.5 billion, equating to a share price in the low-to-mid $50s. This acquisition centers around Soleno's Vykat XR, which is notable for being the first approved treatment for hyperphagia associated with Prader-Willi syndrome. The drug's unique positioning in a concentrated rare disease market grants it significant pricing power, suggesting a monopoly-like advantage. Analysts predict a rapid revenue increase, with forward valuation multiples compressing to an EV/EBITDA of 6.5x and a consensus EPS growth of approximately 900% by 2026. Given these fundamentals, the proposed acquisition price of $50 per share appears justified and may even be conservative if Vykat XR successfully expands into adjacent metabolic conditions.